Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 1542786, 11 pages
http://dx.doi.org/10.1155/2016/1542786
Research Article

CYLD Promotes TNF-α-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells

Department of Thoracic Surgery, Provincial Clinical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China

Received 25 February 2016; Revised 12 August 2016; Accepted 18 August 2016

Academic Editor: Vinod K. Mishra

Copyright © 2016 Xing Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X.-B. Li, J.-D. Gu, and Q.-H. Zhou, “Review of aerobic glycolysis and its key enzymes—new targets for lung cancer therapy,” Thoracic Cancer, vol. 6, no. 1, pp. 17–24, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. N. L. Ausborn, Q. T. Le, J. D. Bradley et al., “Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group,” International Journal of Radiation Oncology, Biology, Physics, vol. 83, no. 4, pp. e453–e464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. Keating, “Nivolumab: a review in advanced squamous non-small cell lung cancer,” Drugs, vol. 75, no. 16, pp. 1925–1934, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. F. J. Cimas, J. Callejas-Valera, R. Pascual-Serra et al., “MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cell,” Oncotarget, vol. 6, no. 42, pp. 44095–44107, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Eliyakin, H. Postaci, Y. Baskin, and Z. Kozacioğlu, “Small cell carcinoma of the urinary bladder: KIT and PDGFRA gene mutations,” Rare Tumors, vol. 7, no. 4, article 5982, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. H. A. Blair and E. D. Deeks, “Albumin-bound paclitaxel: a review in non-small cell lung cancer,” Drugs, vol. 75, no. 17, pp. 2017–2024, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Zhang and B. Cai, “The impact of tobacco on lung health in China,” Respirology, vol. 8, no. 1, pp. 17–21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Zhang, S. Wang, L. Wang et al., “Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review,” OncoTargets and Therapy, vol. 8, pp. 3361–3369, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Y. Li, L. Luo, Y. H. Hu et al., “Lung cancer screening: a systematic review of clinical practice guidelines,” International Journal of Clinical Practice, vol. 70, no. 1, pp. 20–30, 2016. View at Publisher · View at Google Scholar
  10. G. R. Bignell, W. Warren, S. Seal et al., “Identification of the familial cylindromatosis tumour-suppressor gene,” Nature Genetics, vol. 25, no. 2, pp. 160–165, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. T. R. Brummelkamp, S. M. B. Nijman, A. M. G. Dirac, and R. Bernards, “Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB,” Nature, vol. 424, no. 6950, pp. 797–801, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Koga, H. L. Jae, H. Jono et al., “Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling,” The Journal of Biological Chemistry, vol. 283, no. 18, pp. 12546–12554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Takami, H. Nakagami, R. Morishita et al., “Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells,” The American Journal of Pathology, vol. 172, no. 3, pp. 818–829, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Wang, R. A. Baiocchi, S. Pal, G. Mosialos, M. Caligiuri, and S. Sif, “The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene,” Molecular and Cellular Biology, vol. 25, no. 18, pp. 7953–7965, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Massoumi and R. Paus, “Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control,” BioEssays, vol. 29, no. 12, pp. 1203–1214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Hellerbrand and R. Massoumi, “Cylindromatosis—a protective molecule against liver diseases,” Medicinal Research Reviews, vol. 36, no. 2, pp. 342–359, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Trompouki, A. Tsagaratou, S. K. Kosmidis et al., “Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation,” Neoplasia, vol. 11, no. 5, pp. 469–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. R. R. Pannem, C. Dorn, K. Ahlqvist, A. K. Bosserhoff, C. Hellerbrand, and R. Massoumi, “CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma,” Carcinogenesis, vol. 35, no. 2, pp. 461–468, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Hayashi, H. Jono, S. Shinriki et al., “Clinical significance of CYLD downregulation in breast cancer,” Breast Cancer Research and Treatment, vol. 143, no. 3, pp. 447–457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Petrelli, K. Borgonovo, M. Cabiddu, M. Ghilardi, and S. Barni, “Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies,” Expert Review of Anticancer Therapy, vol. 12, no. 10, pp. 1299–1312, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Barnett, V. W. Rusch, J. Zheng et al., “Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases,” Journal of Thoracic Oncology, vol. 6, no. 9, pp. 1530–1536, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Guo, S. Shinriki, Y. Su et al., “Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy,” Oncotarget, vol. 5, no. 15, pp. 6353–6364, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Kovalenko, C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, and G. Courtois, “The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination,” Nature, vol. 424, no. 6950, pp. 801–805, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Trompouki, E. Hatzivassillou, T. Tsichritzis, H. Farmer, A. Ashworth, and G. Mosialos, “CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members,” Nature, vol. 424, no. 6950, pp. 793–796, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Miliani de Marval, S. Lutfeali, J. Y. Jin, B. Leshin, M. Angelica Selim, and J. Y. Zhang, “CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels,” Cancer Prevention Research, vol. 4, no. 6, pp. 851–859, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Yoshida, H. Jono, H. Kai, and J.-D. Li, “The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7,” The Journal of Biological Chemistry, vol. 280, no. 49, pp. 41111–41121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Rajan, R. J. R. Elliott, A. Smith et al., “The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling,” Oncotarget, vol. 5, no. 23, pp. 12126–12140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Liu, B. Xu, W. Shen et al., “Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1,” Leukemia, vol. 26, no. 6, pp. 1293–1300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Zheng, L. Hu, W. Huang et al., “CYLD mutation causes multiple familial trichoepithelioma in three Chinese families,” Human Mutation, vol. 23, no. 4, article 400, 2004. View at Google Scholar · View at Scopus
  30. L. L. Deng, Y. X. Shao, H. F. Lv, H. B. Deng, and F. Z. Lv, “Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells,” Neoplasma, vol. 59, no. 1, pp. 18–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Leonard, R. Chaggar, C. Jones, M. Takahashi, A. Nikitopoulou, and S. R. Lakhani, “Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours,” Journal of Clinical Pathology, vol. 54, no. 9, pp. 689–692, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Zhong, C. R. Fields, N. Su, Y.-X. Pan, and K. D. Robertson, “Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer,” Oncogene, vol. 26, no. 18, pp. 2621–2634, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Wu, K. J. Shi, J. J. An et al., “The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells,” Cell Death & Disease, vol. 5, no. 2, Article ID e1085, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Chromik, C. Safferthal, H. Serve, and S. Fulda, “Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis,” Cancer Letters, vol. 344, no. 1, pp. 101–109, 2014. View at Publisher · View at Google Scholar · View at Scopus